Table 5.
Prognostic evaluation of clinical and histopatological characteristics of late stages: Progression Free Survival
| Progression Free Survival - Univariated analysis | |||||
|---|---|---|---|---|---|
| HR | Lower 95% CI | Upper 95% CI | p-value | ||
| Age at diagnosis | 1.02 | 1.01 | 1.03 | p <0.001 | |
| Stage | III | 1 | |||
| IV | 1.33 | 0.86 | 2.05 | 0.206 | |
| Grading | G1 | 1 | |||
| G2 | 2.14 | 1.05 | 4.34 | 0.035 | |
| G3 | 2.13 | 1.08 | 4.20 | 0.029 | |
| Histotype | Serous | 1 | |||
| Endometroid | 1.18 | 0.72 | 1.92 | 0.516 | |
| Clear cell | 1.21 | 0.66 | 2.24 | 0.535 | |
| Mucinous | 1.90 | 0.93 | 3.87 | 0.078 | |
| Undifferentiated | 1.01 | 0.42 | 2.47 | 0.977 | |
| Other | 0.30 | 0.04 | 2.13 | 0.227 | |
| Residual tumor | < 2 cm | 1 | |||
| ≥ 2 cm | 1.83 | 1.33 | 2.51 | p <0.001 | |
| KRAS gene copy number | Disomy | 1 | |||
| Amplification | 1.11 | 0.78 | 1.59 | 0.556 | |
| Deletion | 1.69 | 0.99 | 2.86 | 0.054 | |
| KRAS-LCS6 polymorphism | T/G-G/G | 1 | |||
| T/T | 1.04 | 0.72 | 1.51 | 0.831 | |
| Progression Free Survival - Multivariated analysis | |||||
| HR | Lower 95% CI | Upper 95% CI | p-value | ||
| KRAS-LCS6 polymorphism | T/G-G/G | 1 | |||
| T/T | 1.19 | 0.80 | 1.76 | 0.383 | |